Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $534000.0.

  • Spero Therapeutics' Non Operating Income fell 5380.62% to $534000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year decrease of 3063.22%. This contributed to the annual value of $4.8 million for FY2024, which is 2222.79% up from last year.
  • Per Spero Therapeutics' latest filing, its Non Operating Income stood at $534000.0 for Q3 2025, which was down 5380.62% from $744000.0 recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Non Operating Income ranged from a high of $1.3 million in Q1 2024 and a low of -$2.6 million during Q1 2022
  • Moreover, its 5-year median value for Non Operating Income was $847000.0 (2022), whereas its average is $255684.2.
  • In the last 5 years, Spero Therapeutics' Non Operating Income tumbled by 222321.43% in 2022 and then skyrocketed by 49119.5% in 2023.
  • Over the past 5 years, Spero Therapeutics' Non Operating Income (Quarter) stood at -$1.5 million in 2021, then skyrocketed by 157.7% to $847000.0 in 2022, then rose by 23.49% to $1.0 million in 2023, then grew by 7.74% to $1.1 million in 2024, then tumbled by 52.62% to $534000.0 in 2025.
  • Its Non Operating Income was $534000.0 in Q3 2025, compared to $744000.0 in Q2 2025 and $865000.0 in Q1 2025.